Skip to main content

Lunai Bioworks Inc.

corporate_fare Company Profile

Lunai Bioworks Inc.

LNAI·NASDAQ·Life Sciences·CIK 0001527728

Lunai Bioworks Inc. is an AI-driven biotechnology company focused on precision medicine, biomarker discovery, and therapeutic development for central nervous system (CNS) disorders, biodefense, and other serious diseases with unmet medical need. As of June 30, 2026, the company operated principally through two operating subsidiaries: Renovaro Biosciences and BioSymetrics. A third wholly owned subsidiary, Lunai Bioworks IP, Inc., holds intellectual property, including the N2B intranasal drug delivery platform, acquired in the May 2026 Neurobridge acquisition. BioSymetrics refers to BioSymetrics Inc. and its wholly owned subsidiary BioSymetrics Corp., which were acquired on April 8, 2025. During the quarter ended September 30, 2025, GEDi Cube B.V., acquired on February 13, 2024, filed for bankruptcy and ceased operations. Following GEDi Cube's bankruptcy and deconsolidation, Lunai Bioworks Inc. continued its AI-driven precision medicine and biomarker discovery strategy through BioSymetrics. BioSymetrics' existing AI and machine-learning platform provided capabilities that overlapped with GEDi Cube's cancer diagnostics and biomarker discovery objectives, while also supporting therapeutic development, central nervous system disorders, and biodefense. BioSymetrics continued pursuing cancer-related diagnostic and biomarker opportunities and expanded research and business development into additional therapeutic areas. The company's consolidated operations consist principally of Renovaro Biosciences' cell and gene therapy programs and BioSymetrics' AI-driven biotechnology platform. Lunai Bioworks Inc. combines multimodal data analytics with experimental biology to generate predictive insights to accelerate research and development and improve the efficiency of therapeutic and chemical countermeasure discovery.

Lunai Bioworks Inc. (NASDAQ:LNAI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for LNAI at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Lunai Bioworks Acquires CNS Patent Portfolio via $20M Preferred Stock Issuance, Bolstering Nasdaq Equity Compliance
  • Lunai Bioworks Delays Key Shareholder Vote to Secure Quorum for Reverse Split
  • Lunai Bioworks Postpones Special Meeting to Secure Quorum for Critical Reverse Stock Split Vote
  • Lunai Bioworks Postpones Special Meeting to May 8th to Secure Reverse Stock Split Vote Amid Delisting Threat
  • Lunai Bioworks Schedules Shareholder Vote on Second Reverse Stock Split to Avoid Nasdaq Delisting

Financial Snapshot

Fiscal year ended June 30, 2026
Revenue
$51.99K
Net Income
-$3.56M
Diluted EPS
-$1.06
Op. Cash Flow
-$5.29M
Free Cash Flow
-$5.29M
Operating Income
-$8.7M
Cash & Equivalents
$1.71M
Debt / Equity
0.00×
Net Margin
-68.52×
Shares Outstanding
4.62M sh
Source: 10-K · filed 2026-10-13 · accession 0001731122-26-001339

No longer listed

LNAI (Lunai Bioworks Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed LNAI - Filings & News (Page 2)

LNAI
May 01, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
9
LNAI
Apr 28, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
7
LNAI
Apr 28, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
7
LNAI
Apr 28, 2026, 5:00 PM EDT
Filing Type: DEFA14A
Importance Score:
7
LNAI
Apr 13, 2026, 5:15 PM EDT
Filing Type: DEF 14A
Importance Score:
8
LNAI
Apr 02, 2026, 5:01 PM EDT
Filing Type: PRE 14A
Importance Score:
8
LNAI
Mar 26, 2026, 8:52 AM EDT
Source: Reuters
Importance Score:
9
LNAI
Mar 05, 2026, 4:46 PM EST
Filing Type: 8-K
Importance Score:
9
LNAI
Feb 23, 2026, 4:33 PM EST
Filing Type: 8-K
Importance Score:
8
LNAI
Feb 17, 2026, 3:16 PM EST
Filing Type: 10-Q
Importance Score:
9
LNAI
Feb 12, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
9
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets